Pharma's Almanac’s Post

Revolutionizing AVV gene therapy production with cutting-edge mass photometry technology! 🚀 Discover how Rentschler Biopharma and its partners are setting new standards in quality and efficiency. #GeneTherapy #AAV #Innovation

Transforming the future of AAV gene therapy! Explore how Rentschler Biopharma's innovative mass photometry approach is driving breakthroughs in quality and precision. #AdvancedTherapies #MassPhotometry #GeneTherapy

Cell and gene therapy has often made headlines due to its nontraditional cost model, but the value of this transformative medicine is often overlooked. ARM's Gene Therapy for Patients and Society (GPS) framework, released at the Biotech Showcase during #JPM24, and CAR-T Therapy for Patients and Society (CAR-PS) framework, released last month, demonstrate how these advanced medicines are poised to provide incredible value. Unpack both value frameworks on our website here: https://lnkd.in/eX2TJiYf

Gain insights into the current top challenges in cell and gene therapy and their solutions from Catherine BUCHERE at this year's ESACT. Learn more about Sartorius cell and gene therapy solutions: https://sar.to/0i1cj #SimplifyingProgress #InThisTogether #AdvancedTherapies #CellandGeneTherapy #ESACT #ESACT2024

Presented at the 66th ASH Annual Meeting, Expression Therapeutics' Phase I trial for ET3 — a cutting-edge gene therapy for #hemophilia A — shows promising results! The trial revealed significant clinical benefits with no unexpected safety concerns. Discover how this innovation could shape the future of care. https://bit.ly/49ReOJQ #ASH2024

Fresenius Kabi is pleased to support other industry leaders in the Cell and Gene Therapy space. Be sure to check out Cellular Origins recent whitepaper titled “How to De-Risk Cell and Gene Therapy Manufacturing” detailing their approach in overcoming these barriers. https://bit.ly/3ZHiVnf #CellAndGeneTherapy #MedTech #CommittedToLife

Important aspects of plasmid DNA purity are explained in the new article "Assessing pDNA Purity For Cell & Gene Therapies" by our senior analytical consultant Brian Glass. The application of conventional development methods to the difficulties encountered in producing gene therapy products is examined in this article. Brian highlights the upcoming USP 1040 chapter and offers advice on developing successful control measures for plasmid DNA, a crucial building block in the industry. https://hubs.ly/Q02zMqzM0

Significant advances in upstream biomanufacturing methods for cell and gene therapies have been achieved in recent years. However, final yields continue to be impacted by losses in downstream steps. Interferometric light microscopy (ILM) represents a fast and cost-effective method for process development teams to obtain size and concentration data within seconds. Learn more in this upcoming webinar with Cell & Gene Therapy Insights presented by Benjamin Josey: http://ms.spr.ly/6045WHOvb

From a FB friend: “The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter wrote in the note to clients Tuesday. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”

If you want to learn more about the operational challenges running clinical trials using gene therapies you should not miss Lakshmi GUDURI presentation!